Dr. Delin Liu 刘德林
Chief Physician
Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical oncology for digestive tract, head and neck, breast, lung, and neuroendocrine tumors. Focuses on chemotherapy, targeted therapy, and immunotherapy.
Dr. Liu holds a medical doctorate and has nearly 20 years of clinical experience in medical oncology. The doctor has led or participated in multiple national and provincial research projects, published nearly 20 papers in core academic journals, and co-authored three oncology monographs.
Professional roles
- Member, Esophageal Cancer Committee, Beijing Cancer Society
- Youth Member, First Gastric Cancer Committee, Jiangsu Anti-Cancer Association
- Deputy Leader, Neuroendocrinology Group of Chemotherapy and Biotherapy, Jiangsu Province
- Member, Esophageal and Colorectal Cancer Committees, Jiangsu Anti-Cancer Alliance
Name order: in Chinese the family name comes first (Liu Delin). Papers usually list the name as Delin Liu or Liu D.
Selected publications
16 papers on PubMed matched by name and affiliation; 6 as first or senior author since 2016. Most recent first- or senior-author papers:
- NPJ Precis Oncol, 2026 (senior author): HMGB3 facilitates malignant phenotype of esophageal carcinoma via histone lactylation- and Wnt/β-catenin-dependent transcription activation of c-myc. PubMed 42323461
- Hum Vaccin Immunother, 2025 (senior author): Efficacy and safety analysis of immune checkpoint inhibitor rechallenge in advanced esophageal squamous cell carcinoma: A retrospective study. PubMed 41287859
- Cell Signal, 2024 (senior author): CircATXN7 regulates the proliferation and invasion of esophageal cancer cells through miR-4319/NLRC5. PubMed 39121974
- J Gastrointest Oncol, 2022 (first author): Expression of CircATXN7 in esophageal cancer tissues and its effect on cell proliferation and invasion. PubMed 35837168
- Curr Mol Pharmacol, 2020 (senior author): miR-4319 Suppresses the Growth of Esophageal Squamous Cell Carcinoma Via Targeting NLRC5. PubMed 31746301
- Biomed Pharmacother, 2019 (senior author): Long non-coding RNA XIST promotes the development of esophageal cancer by sponging miR-494 to regulate CDK6 expression. PubMed 30551480
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion